Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B

Eligible patients are randomly allocated with a 1:1 ratio to continue viral suppression or stop the treatment (entecavir or tenofovir). Patients will be followed up for 3 years. For patients who are assigned to the finite Nuc therapy, they should be monitored monthly for the initial 3 months and then every 3-6 months thereafter for relapse.

Continuation of either entecavir or tenofovir treatment for 3 years